Renaissance Technologies
KBIO

Renaissance Technologies’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Renaissance Technologies’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-110,522
Closed -$2.61M – 3742
2015
Q4 		$2.61M Sell
110,522
-25,088
-19% -$278K 0.01% 1942
2015
Q3 		$259K Buy
135,610
+65,026
+92% +$171K ﹤0.01% 2826
2015
Q2 		$271K Buy
70,584
+26,810
+61% +$114K ﹤0.01% 2914
2015
Q1 		$172K Buy
43,774
+10,661
+32% +$47.8K ﹤0.01% 2923
2014
Q4 		$458K Buy
33,113
+17,255
+109% +$246K ﹤0.01% 2461
2014
Q3 		$197K Sell
15,858
-14,805
-48% -$204K ﹤0.01% 2556
2014
Q2 		$559K Buy
30,663
+27,008
+739% +$462K ﹤0.01% 2283
2014
Q1 		$79K Buy
3,655
+1,339
+58% +$38.8K ﹤0.01% 2729
2013
Q4 		$82K Buy
+2,316
New +$77.6K ﹤0.01% 2752

Other funds holding KBIO

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Renaissance Technologies's KBIO Position: Q1 2016 in Review

Renaissance Technologies sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q1 2016, closing a stake of 110,522 shares — an estimated $2.61M sold.

Renaissance Technologies first reported a position in KBIO in Q4 2013 and held it in 9 quarters. The position peaked at $2.61M in Q4 2015. 1 fund tracked by Wall St. Rank holds KBIO as of Q1 2016.

  • Renaissance Technologies reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q1 2016 after selling out during the quarter.
  • Renaissance Technologies sold 110,522 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q1 2016, an estimated $2.61M.
  • Renaissance Technologies first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q4 2013 and held it in 9 quarters.
  • Renaissance Technologies's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $2.61M in Q4 2015.
  • 1 fund tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q1 2016.

Based on Renaissance Technologies's 13F filing for Q1 2016, filed 13 May 2016.